nach oben

Endocrine

Erschienen in:

04.05.2016 | Mini Review

Gynecomastia and hormones

verfasst von: Andrea Sansone, Francesco Romanelli, Massimiliano Sansone, Andrea Lenzi, Luigi Di Luigi

Erschienen in: Endocrine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Gynecomastia—the enlargement of male breast tissue in men—is a common finding, frequently observed in newborns, adolescents, and old men. Physiological gynecomastia, occurring in almost 25 % of cases, is benign and self-limited; on the other hand, several conditions and drugs may induce proliferation of male breast tissue. True gynecomastia is a common feature often related to estrogen excess and/or androgen deficiency as a consequence of different endocrine disorders. Biochemical evaluation should be performed once physiological or iatrogenic gynecomastia has been ruled out. Non-endocrine illnesses, including liver failure and chronic kidney disease, are another cause of gynecomastia which should be considered. Treating the underlying disease or discontinuing medications might resolve gynecomastia, although the psychosocial burden of this condition might require different and careful consideration.

N. Cuhaci, S.B. Polat, B. Evranos, R. Ersoy, B. Cakir, Gynecomastia: clinical evaluation and management. Indian J Endocrinol Metab 18(2), 150–158 (2014). doi:10.4103/2230-8210.129104 CrossRefPubMedPubMedCentral

R.E. Johnson, M.H. Murad, Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin. Proc. 84(11), 1010–1015 (2009). doi:10.1016/S0025-6196(11)60671-X CrossRefPubMedPubMedCentral

R.E. Johnson, C.A. Kermott, M.H. Murad, Gynecomastia—evaluation and current treatment options. Ther. Clin. Risk Manag. 7, 145–148 (2011). doi:10.2147/TCRM.S10181 PubMedPubMedCentral

R. Mathur, G.D. Braunstein, Gynecomastia: pathomechanisms and treatment strategies. Horm. Res. 48(3), 95–102 (1997)CrossRefPubMed

B. Ladizinski, K.C. Lee, F.N. Nutan, H.W. Higgins II, D.G. Federman, Gynecomastia: etiologies, clinical presentations, diagnosis, and management. South. Med. J. 107(1), 44–49 (2014). doi:10.1097/SMJ.0000000000000033 CrossRefPubMed

M. Kipling, J.E. Ralph, K. Callanan, Psychological impact of male breast disorders: literature review and survey results. Breast Care (Basel) 9(1), 29–33 (2014). doi:10.1159/000358751 CrossRef

H.S. Narula, H.E. Carlson, Gynaecomastia–pathophysiology, diagnosis and treatment. Nat Rev Endocrinol 10(11), 684–698 (2014). doi:10.1038/nrendo.2014.139 CrossRefPubMed

L. Rew, C. Young, T. Harrison, R. Caridi, A systematic review of literature on psychosocial aspects of gynecomastia in adolescents and young men. J. Adolesc. 43, 206–212 (2015). doi:10.1016/j.adolescence.2015.06.007 CrossRefPubMed

G.D. Braunstein, Clinical practice. Gynecomastia. N. Engl. J. Med. 357(12), 1229–1237 (2007). doi:10.1056/NEJMcp070677 CrossRefPubMed

10.

E. Sloand, Pediatric and adolescent breast health. Lippincotts Prim. Care Pract. 2(2), 170–175 (1998)PubMed

11.

G. Dickson, Gynecomastia. Am. Fam. Physician 85(7), 716–722 (2012)PubMed

12.

G.D. Braunstein, Aromatase and gynecomastia. Endocr. Relat. Cancer 6(2), 315–324 (1999)CrossRefPubMed

13.

R.S. Swerdloff, J. Ng, Gynecomastia: etiology, diagnosis, and treatment, in Endotext, ed. by L.J. De Groot, P. Beck-Peccoz, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, C. Koch, R. McLachlan, M. New, R. Rebar, F. Singer, A. Vinik, M.O. Weickert (MDText.com, Inc, South Dartmouth, MA, 2000)

14.

N. Rokutanda, T. Iwasaki, H. Odawara, R. Nagaoka, W. Miyazaki, A. Takeshita, Y. Koibuchi, J. Horiguchi, N. Shimokawa, Y. Iino, Y. Morishita, N. Koibuchi, Augmentation of estrogen receptor-mediated transcription by steroid and xenobiotic receptor. Endocrine 33(3), 305–316 (2008). doi:10.1007/s12020-008-9091-9 CrossRefPubMed

15.

S.A. Bembo, H.E. Carlson, Gynecomastia: its features, and when and how to treat it. Clevel. Clin. J. Med. 71(6), 511–517 (2004)CrossRef

16.

R.N. Morcos, T. Kizy, Gynecomastia: when is treatment indicated? J. Fam. Pract. 61(12), 719–725 (2012)PubMed

17.

E. Nieschlag, Klinefelter syndrome: the commonest form of hypogonadism, but often overlooked or untreated. Dtsch. Arztebl. Int. 110(20), 347–353 (2013). doi:10.3238/arztebl.2013.0347 PubMedPubMedCentral

18.

F. Lanfranco, A. Kamischke, M. Zitzmann, E. Nieschlag, Klinefelter’s syndrome. Lancet 364(9430), 273–283 (2004). doi:10.1016/S0140-6736(04)16678-6 CrossRefPubMed

19.

L.A. Brinton, Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatr. 100(6), 814–818 (2011). doi:10.1111/j.1651-2227.2010.02131.x CrossRefPubMedPubMedCentral

20.

M. Galdiero, R. Pivonello, L.F. Grasso, A. Cozzolino, A. Colao, Growth hormone, prolactin, and sexuality. J. Endocrinol. Investig. 35(8), 782–794 (2012). doi:10.1007/BF03345805 CrossRef

21.

M. Maggi, J. Buvat, G. Corona, A. Guay, L.O. Torres, Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J. Sex Med. 10(3), 661–677 (2013). doi:10.1111/j.1743-6109.2012.02735.x CrossRefPubMed

22.

A. Sansone, F. Romanelli, D. Gianfrilli, A. Lenzi, Endocrine evaluation of erectile dysfunction. Endocrine 46(3), 423–430 (2014). doi:10.1007/s12020-014-0254-6 CrossRefPubMed

23.

M. Ferreira, M. Mesquita, M. Quaresma, S. Andre, Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology 53(1), 56–61 (2008). doi:10.1111/j.1365-2559.2008.03059.x CrossRefPubMed

24.

H.C. Mertani, T. Garcia-Caballero, A. Lambert, F. Gerard, C. Palayer, J.M. Boutin, B.K. Vonderhaar, M.J. Waters, P.E. Lobie, G. Morel, Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer 79(2), 202–211 (1998). doi:10.1002/(SICI)1097-0215(19980417)79:2<202:AID-IJC17>3.0.CO;2-B CrossRefPubMed

25.

R.C. Hovey, J.F. Trott, E. Ginsburg, A. Goldhar, M.M. Sasaki, S.J. Fountain, K. Sundararajan, B.K. Vonderhaar, Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland. Dev. Dyn. 222(2), 192–205 (2001). doi:10.1002/dvdy.1179 CrossRefPubMed

26.

M.L. Bravo, M.P. Pinto, I. Gonzalez, B. Oliva, S. Kato, M.A. Cuello, C.A. Lange, G.I. Owen, Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor. Endocrine 48(1), 309–320 (2015). doi:10.1007/s12020-014-0288-9 CrossRefPubMed

27.

F. Chentli, I. Bekkaye, S. Azzoug, Feminizing adrenocortical tumors: literature review. Indian J. Endocrinol. Metab. 19(3), 332–339 (2015). doi:10.4103/2230-8210.152764 CrossRefPubMedPubMedCentral

28.

S. Kayemba-Kays, G. Fromont-Hankard, G. Lettelier, S. Gabriel, G. Levard, Leydig cell tumour revealed by bilateral gynecomastia in a 15-year-old adolescent: a patient report. J. Pediatr. Endocrinol. Metab. 23(11), 1195–1199 (2010)PubMed

29.

H. Djaladat, C. Nichols, S. Daneshmand, Androgen-producing testicular germ cell tumors. J. Clin. Oncol. 29(21), e634–e635 (2011). doi:10.1200/JCO.2011.35.1965 CrossRefPubMed

30.

N. Kolitsas, S. Tsambalas, F. Dimitriadis, D. Baltogiannis, E. Vlachopoulou, S. Vappa, D. Giannakis, P. Tsounapi, A. Takenaka, N. Sofikitis, Gynecomastia as a first clinical sign of nonseminomatous germ cell tumor. Urol. Int. 87(2), 248–250 (2011). doi:10.1159/000328387 CrossRefPubMed

31.

S. Kaptanis, L. Parvanta, L. Beltran, Testicular seminoma presenting as unilateral gynecomastia. Breast J. 20(4), 424–426 (2014). doi:10.1111/tbj.12287 CrossRefPubMed

32.

S.M. Stevenson, W.T. Lowrance, Epidemiology and diagnosis of testis cancer. Urol. Clin. N. Am. 42(3), 269–275 (2015). doi:10.1016/j.ucl.2015.04.001 CrossRef

33.

B. Hayes-Lattin, C.R. Nichols, Testicular cancer: a prototypic tumor of young adults. Semin. Oncol. 36(5), 432–438 (2009). doi:10.1053/j.seminoncol.2009.07.006 CrossRefPubMedPubMedCentral

34.

Y. Huang, J. Song, M. Xu, Q. Zan, Primary Leydig cell tumour of epididymis: a rare case report with review of literature. Andrologia 45(6), 430–433 (2013). doi:10.1111/and.12049 CrossRefPubMed

35.

F. Deepinder, G.D. Braunstein, Drug-induced gynecomastia: an evidence-based review. Expert Opin. Drug Saf. 11(5), 779–795 (2012). doi:10.1517/14740338.2012.712109 CrossRefPubMed

36.

M.G. Forest, A. Lecoq, J.M. Saez, Kinetics of human chorionic gonadotropin-induced steroidogenic response of the human testis. II. Plasma 17 α-hydroxyprogesterone, δ4-androstenedione, estrone, and 17 β-estradiol: evidence for the action of human chorionic gonadotropin on intermediate enzymes implicated in steroid biosynthesis. J. Clin. Endocrinol. Metab. 49(2), 284–291 (1979). doi:10.1210/jcem-49-2-284 CrossRefPubMed

37.

S.A. Berson, S.S. Schreiber, Gynecomastia and hyperthyroidism. J. Clin. Endocrinol. Metab. 13(9), 1126–1128 (1953). doi:10.1210/jcem-13-9-1126 CrossRefPubMed

38.

K.L. Becker, J.L. Winnacker, M.J. Matthews, G.A. Higgins Jr, Gynecomastia and hyperthyroidism. An endocrine and histological investigation. J. Clin. Endocrinol. Metab. 28(2), 277–285 (1968). doi:10.1210/jcem-28-2-277 CrossRefPubMed

39.

H.K. Ho, K.C. Loh, Hyperthyroidism with gynaecomastia as the initial complaint: a case report. Ann. Acad. Med. Singapore 27(4), 594–596 (1998)PubMed

40.

W.B. Chan, V.T. Yeung, C.C. Chow, W.Y. So, C.S. Cockram, Gynaecomastia as a presenting feature of thyrotoxicosis. Postgrad. Med. J. 75(882), 229–231 (1999)CrossRefPubMedPubMedCentral

41.

E.A. Jannini, S. Ulisse, M. D’Armiento, Thyroid hormone and male gonadal function. Endocr. Rev. 16(4), 443–459 (1995). doi:10.1210/edrv-16-4-443 PubMed

42.

A.W. Meikle, The interrelationships between thyroid dysfunction and hypogonadism in men and boys. Thyroid 14(Suppl 1), S17–25 (2004). doi:10.1089/105072504323024552 CrossRefPubMed

43.

G.E. Krassas, K. Poppe, D. Glinoer, Thyroid function and human reproductive health. Endocr. Rev. 31(5), 702–755 (2010). doi:10.1210/er.2009-0041 CrossRefPubMed

44.

M. Caprio, E. Fabbrini, A.M. Isidori, A. Aversa, A. Fabbri, Leptin in reproduction. Trends Endocrinol. Metab. 12(2), 65–72 (2001)CrossRefPubMed

45.

M.J. Vazquez, A. Romero-Ruiz, M. Tena-Sempere, Roles of leptin in reproduction, pregnancy and polycystic ovary syndrome: consensus knowledge and recent developments. Metabolism 64(1), 79–91 (2015). doi:10.1016/j.metabol.2014.10.013 CrossRefPubMed

46.

A. Sansone, F. Romanelli, E.A. Jannini, A. Lenzi, Hormonal correlations of premature ejaculation. Endocrine 49(2), 333–338 (2015). doi:10.1007/s12020-014-0520-7 CrossRefPubMed

47.

I.S. Farooqi, S. O’Rahilly, 20 Years of leptin: human disorders of leptin action. J. Endocrinol. 223(1), T63–T70 (2014). doi:10.1530/JOE-14-0480 CrossRefPubMed

48.

B. Dundar, N. Dundar, T. Erci, E. Bober, A. Buyukgebiz, Leptin levels in boys with pubertal gynecomastia. J. Pediatr. Endocrinol. Metab. 18(10), 929–934 (2005)CrossRefPubMed

49.

E. Eren, T. Edgunlu, H.A. Korkmaz, E.D. Cakir, K. Demir, E.S. Cetin, S.K. Celik, Genetic variants of estrogen beta and leptin receptors may cause gynecomastia in adolescent. Gene 541(2), 101–106 (2014). doi:10.1016/j.gene.2014.03.013 CrossRefPubMed

50.

S. Catalano, S. Marsico, C. Giordano, L. Mauro, P. Rizza, M.L. Panno, S. Ando, Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J. Biol. Chem. 278(31), 28668–28676 (2003). doi:10.1074/jbc.M301695200 CrossRefPubMed

51.

S. Catalano, L. Mauro, S. Marsico, C. Giordano, P. Rizza, V. Rago, D. Montanaro, M. Maggiolini, M.L. Panno, S. Ando, Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J. Biol. Chem. 279(19), 19908–19915 (2004). doi:10.1074/jbc.M313191200 CrossRefPubMed

52.

M.N. Dieudonne, A. Sammari, E. Dos Santos, M.C. Leneveu, Y. Giudicelli, R. Pecquery, Sex steroids and leptin regulate 11 β-hydroxysteroid dehydrogenase I and P450 aromatase expressions in human preadipocytes: sex specificities. J. Steroid Biochem. Mol. Biol. 99(4–5), 189–196 (2006). doi:10.1016/j.jsbmb.2006.01.007 CrossRefPubMed

53.

B. Lapauw, G. T’Sjoen, A. Mahmoud, J.M. Kaufman, J.B. Ruige, Short-term aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men. Eur. J. Endocrinol. 160(3), 397–402 (2009). doi:10.1530/EJE-08-0881 CrossRefPubMed

54.

C.N. Habib, A.M. Al-Abd, M.F. Tolba, A.E. Khalifa, A. Khedr, H.A. Mosli, A.B. Abdel-Naim, Leptin influences estrogen metabolism and accelerates prostate cell proliferation. Life Sci. 121(C), 10–15 (2015). doi:10.1016/j.lfs.2014.11.007 CrossRefPubMed

55.

S.T. Ng, J. Zhou, O.O. Adesanya, J. Wang, D. LeRoith, C.A. Bondy, Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat. Med. 3(10), 1141–1144 (1997)CrossRefPubMed

56.

M.G. Mieritz, K. Sorensen, L. Aksglaede, A. Mouritsen, C.P. Hagen, L. Hilsted, A.M. Andersson, A. Juul, Elevated serum IGF-I, but unaltered sex steroid levels, in healthy boys with pubertal gynaecomastia. Clin. Endocrinol. (Oxf.) 80(5), 691–698 (2014). doi:10.1111/cen.12323 CrossRef

57.

L.J. De Groot, P. Beck-Peccoz, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, C. Koch, R. McLachlan, M. New, R. Rebar, F. Singer, A. Vinik, M.O. Weickert, R.S. Swerdloff, J. Ng, Gynecomastia: etiology, diagnosis, and treatment, vol. 53 (MDText.com, Inc, South Dartmouth, MA, 2000)

58.

M.G. Mieritz, L.L. Raket, C.P. Hagen, J.E. Nielsen, M.L. Talman, J.H. Petersen, S.H. Sommer, K.M. Main, N. Jorgensen, A. Juul, A longitudinal study of growth, sex steroids, and IGF-1 in boys with physiological gynecomastia. J. Clin. Endocrinol. Metab. 100(10), 3752–3759 (2015). doi:10.1210/jc.2015-2836 CrossRefPubMed

59.

F.M. Souza, P.F. Collett-Solberg, Adverse effects of growth hormone replacement therapy in children. Arq. Bras. Endocrinol. Metab. 55(8), 559–565 (2011)CrossRef

60.

H. Liu, D.M. Bravata, I. Olkin, S. Nayak, B. Roberts, A.M. Garber, A.R. Hoffman, Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann. Intern. Med. 146(2), 104–115 (2007)CrossRefPubMed

61.

S.V. Acharya, R.A. Gopal, T.R. Bandgar, P.S. Menon, N.S. Shah, Prepubertal gynecomastia a rare complication of growth hormone therapy. Indian J. Pediatr. 77(4), 443–444 (2010). doi:10.1007/s12098-010-0012-6 CrossRefPubMed

62.

D.B. Young, 6′6″ United States marine seeks treatment for gynecomastia only to learn it is all in his head. Mil. Med. 180(12), e1290–e1292 (2015). doi:10.7205/MILMED-D-15-00248 CrossRefPubMed

63.

M. Derkacz, I. Chmiel-Perzynska, A. Nowakowski, Gynecomastia—a difficult diagnostic problem. Endokrynol. Pol. 62(2), 190–202 (2011)PubMed

64.

M. Sinclair, M. Grossmann, P.J. Gow, P.W. Angus, Testosterone in men with advanced liver disease: abnormalities and implications. J. Gastroenterol. Hepatol. 30(2), 244–251 (2015). doi:10.1111/jgh.12695 CrossRefPubMed

65.

P. Iglesias, J.J. Carrero, J.J. Diez, Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J. Nephrol. 25(1), 31–42 (2012). doi:10.5301/JN.2011.8481 CrossRefPubMed

66.

W. Krause, Drug-inducing gynaecomastia—a critical review. Andrologia 44(Suppl 1), 621–626 (2012). doi:10.1111/j.1439-0272.2011.01240.x CrossRefPubMed

67.

J.D. Bowman, H. Kim, J.J. Bustamante, Drug-induced gynecomastia. Pharmacotherapy 32(12), 1123–1140 (2012). doi:10.1002/phar.1138 CrossRefPubMed

68.

L. Di Luigi, F. Romanelli, A. Lenzi, Androgenic–anabolic steroids abuse in males. J. Endocrinol. Investig. 28(3 Suppl), 81–84 (2005)

69.

L. Di Luigi, F. Romanelli, P. Sgro, A. Lenzi, Andrological aspects of physical exercise and sport medicine. Endocrine 42(2), 278–284 (2012). doi:10.1007/s12020-012-9655-6 CrossRefPubMed

70.

E. Nieschlag, E. Vorona, Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur. J. Endocrinol. 173(2), R47–R58 (2015). doi:10.1530/EJE-15-0080 CrossRefPubMed

71.

S. Basaria, Androgen abuse in athletes: detection and consequences. J. Clin. Endocrinol. Metab. 95(4), 1533–1543 (2010). doi:10.1210/jc.2009-1579 CrossRefPubMed

72.

A. Momaya, M. Fawal, R. Estes, Performance-enhancing substances in sports: a review of the literature. Sports Med. 45(4), 517–531 (2015). doi:10.1007/s40279-015-0308-9 CrossRefPubMed

73.

V. Birzniece, Doping in sport: effects, harm and misconceptions. Intern. Med. J. 45(3), 239–248 (2015). doi:10.1111/imj.12629 CrossRefPubMed

74.

A. Eckman, A. Dobs, Drug-induced gynecomastia. Expert Opin. Drug Saf. 7(6), 691–702 (2008). doi:10.1517/14740330802442382 CrossRefPubMed

75.

J. Martinez, J.E. Lewi, An unusual case of gynecomastia associated with soy product consumption. Endocr. Pract. 14(4), 415–418 (2008). doi:10.4158/EP.14.4.415 CrossRefPubMed

76.

M. Messina, Soybean isoflavone exposure does not have feminizing effects on men: a critical examination of the clinical evidence. Fertil. Steril. 93(7), 2095–2104 (2010). doi:10.1016/j.fertnstert.2010.03.002 CrossRefPubMed

77.

A. Vivacqua, A.G. Recchia, G. Fasanella, S. Gabriele, A. Carpino, V. Rago, M.L. Di Gioia, A. Leggio, D. Bonofiglio, A. Liguori, M. Maggiolini, The food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. Endocrine 22(3), 275–284 (2003). doi:10.1385/ENDO:22:3:275 CrossRefPubMed

78.

D.V. Henley, N. Lipson, K.S. Korach, C.A. Bloch, Prepubertal gynecomastia linked to lavender and tea tree oils. N. Engl. J. Med. 356(5), 479–485 (2007). doi:10.1056/NEJMoa064725 CrossRefPubMed

79.

L.R. Chadwick, D. Nikolic, J.E. Burdette, C.R. Overk, J.L. Bolton, R.B. van Breemen, R. Frohlich, H.H. Fong, N.R. Farnsworth, G.F. Pauli, Estrogens and congeners from spent hops (Humulus lupulus). J. Nat. Prod. 67(12), 2024–2032 (2004). doi:10.1021/np049783i CrossRefPubMed

80.

R.D. Goldman, Drug-induced gynecomastia in children and adolescents. Can. Fam. Phys. 56(4), 344–345 (2010)

81.

M.A. Sauer, S.M. Rifka, R.L. Hawks, G.B. Cutler Jr, D.L. Loriaux, Marijuana: interaction with the estrogen receptor. J. Pharmacol. Exp. Ther. 224(2), 404–407 (1983)PubMed

Titel: Gynecomastia and hormones
verfasst von: Andrea Sansone
Francesco Romanelli
Massimiliano Sansone
Andrea Lenzi
Luigi Di Luigi
Publikationsdatum: 04.05.2016
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-016-0975-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Hypoxia and extra-cellular matrix gene expression in adipose tissue associates with reduced insulin sensitivity in black South African women

Long-term outcome of multimodal therapy for giant prolactinomas

Breast adiponcosis: a call for further research

Post-prandial anorexigenic gut peptide, appetite and glucometabolic responses at different eating rates in obese patients undergoing laparoscopic sleeve gastrectomy

Persistent hyperparathyroidism due to ectopic parathyroid gland